Global Conjunctivitis 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR062507800

Publication Date:

June 25, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Conjunctivitis market size was valued at US$ 3780 million in 2024 and is forecast to a readjusted size of USD 4209 million by 2031 with a CAGR of 1.6% during review period.
Conjunctivitis, or inflammation of the conjunctiva, is a general term that refers to a diverse group of diseases/disorders that affect the conjunctiva primarily. Most varieties of conjunctivitis are self-limited, but some progress and may cause serious ocular and extraocular complications.
Conjunctivitis is more commonly referred to as pink eye. The whites of the eyes appear pink or red when the conjunctiva (the transparent membrane which lines part of the eyeball) becomes inflamed or infected.
The technical barriers of conjunctivitis industry are existed apparently. The key technology and higher level products are in the hand of the global leading enterprise like Novartis, Santen Pharmaceutical, Bausch + Lomb, Allergan, Sun Pharmaceutical, Akorn and Sinqi, etc.
This report is a detailed and comprehensive analysis for global Conjunctivitis market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by End User. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Conjunctivitis market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Conjunctivitis market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Conjunctivitis market size and forecasts, by Type and by End User, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Conjunctivitis market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Conjunctivitis
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Conjunctivitis market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis (CH), Santen Pharmaceutical (JP), Bausch & Lomb (US), Allergan (US), Sun Pharmaceutical (ID), Akorn (US), Freda (CN), Sinqi (CN), Univision (CN), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Conjunctivitis market is split by Type and by End User. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by End User in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Antibiotic
Pills
Ointment
麻豆原创 segment by End User
Newborns
Children
Adults
Major players covered
Novartis (CH)
Santen Pharmaceutical (JP)
Bausch & Lomb (US)
Allergan (US)
Sun Pharmaceutical (ID)
Akorn (US)
Freda (CN)
Sinqi (CN)
Univision (CN)
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Conjunctivitis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Conjunctivitis, with price, sales quantity, revenue, and global market share of Conjunctivitis from 2020 to 2025.
Chapter 3, the Conjunctivitis competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Conjunctivitis breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by End User, with sales market share and growth rate by Type, by End User, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Conjunctivitis market forecast, by regions, by Type, and by End User, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Conjunctivitis.
Chapter 14 and 15, to describe Conjunctivitis sales channel, distributors, customers, research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Conjunctivitis Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Antibiotic
1.3.3 Pills
1.3.4 Ointment
1.4 麻豆原创 Analysis by End User
1.4.1 Overview: Global Conjunctivitis Consumption Value by End User: 2020 Versus 2024 Versus 2031
1.4.2 Newborns
1.4.3 Children
1.4.4 Adults
1.5 Global Conjunctivitis 麻豆原创 Size & Forecast
1.5.1 Global Conjunctivitis Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Conjunctivitis Sales Quantity (2020-2031)
1.5.3 Global Conjunctivitis Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Novartis (CH)
2.1.1 Novartis (CH) Details
2.1.2 Novartis (CH) Major Business
2.1.3 Novartis (CH) Conjunctivitis Product and Services
2.1.4 Novartis (CH) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Novartis (CH) Recent Developments/Updates
2.2 Santen Pharmaceutical (JP)
2.2.1 Santen Pharmaceutical (JP) Details
2.2.2 Santen Pharmaceutical (JP) Major Business
2.2.3 Santen Pharmaceutical (JP) Conjunctivitis Product and Services
2.2.4 Santen Pharmaceutical (JP) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Santen Pharmaceutical (JP) Recent Developments/Updates
2.3 Bausch & Lomb (US)
2.3.1 Bausch & Lomb (US) Details
2.3.2 Bausch & Lomb (US) Major Business
2.3.3 Bausch & Lomb (US) Conjunctivitis Product and Services
2.3.4 Bausch & Lomb (US) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Bausch & Lomb (US) Recent Developments/Updates
2.4 Allergan (US)
2.4.1 Allergan (US) Details
2.4.2 Allergan (US) Major Business
2.4.3 Allergan (US) Conjunctivitis Product and Services
2.4.4 Allergan (US) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Allergan (US) Recent Developments/Updates
2.5 Sun Pharmaceutical (ID)
2.5.1 Sun Pharmaceutical (ID) Details
2.5.2 Sun Pharmaceutical (ID) Major Business
2.5.3 Sun Pharmaceutical (ID) Conjunctivitis Product and Services
2.5.4 Sun Pharmaceutical (ID) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Sun Pharmaceutical (ID) Recent Developments/Updates
2.6 Akorn (US)
2.6.1 Akorn (US) Details
2.6.2 Akorn (US) Major Business
2.6.3 Akorn (US) Conjunctivitis Product and Services
2.6.4 Akorn (US) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Akorn (US) Recent Developments/Updates
2.7 Freda (CN)
2.7.1 Freda (CN) Details
2.7.2 Freda (CN) Major Business
2.7.3 Freda (CN) Conjunctivitis Product and Services
2.7.4 Freda (CN) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Freda (CN) Recent Developments/Updates
2.8 Sinqi (CN)
2.8.1 Sinqi (CN) Details
2.8.2 Sinqi (CN) Major Business
2.8.3 Sinqi (CN) Conjunctivitis Product and Services
2.8.4 Sinqi (CN) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Sinqi (CN) Recent Developments/Updates
2.9 Univision (CN)
2.9.1 Univision (CN) Details
2.9.2 Univision (CN) Major Business
2.9.3 Univision (CN) Conjunctivitis Product and Services
2.9.4 Univision (CN) Conjunctivitis Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Univision (CN) Recent Developments/Updates
3 Competitive Environment: Conjunctivitis by Manufacturer
3.1 Global Conjunctivitis Sales Quantity by Manufacturer (2020-2025)
3.2 Global Conjunctivitis Revenue by Manufacturer (2020-2025)
3.3 Global Conjunctivitis Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Conjunctivitis by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Conjunctivitis Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Conjunctivitis Manufacturer 麻豆原创 Share in 2024
3.5 Conjunctivitis 麻豆原创: Overall Company Footprint Analysis
3.5.1 Conjunctivitis 麻豆原创: Region Footprint
3.5.2 Conjunctivitis 麻豆原创: Company Product Type Footprint
3.5.3 Conjunctivitis 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Conjunctivitis 麻豆原创 Size by Region
4.1.1 Global Conjunctivitis Sales Quantity by Region (2020-2031)
4.1.2 Global Conjunctivitis Consumption Value by Region (2020-2031)
4.1.3 Global Conjunctivitis Average Price by Region (2020-2031)
4.2 North America Conjunctivitis Consumption Value (2020-2031)
4.3 Europe Conjunctivitis Consumption Value (2020-2031)
4.4 Asia-Pacific Conjunctivitis Consumption Value (2020-2031)
4.5 South America Conjunctivitis Consumption Value (2020-2031)
4.6 Middle East & Africa Conjunctivitis Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Conjunctivitis Sales Quantity by Type (2020-2031)
5.2 Global Conjunctivitis Consumption Value by Type (2020-2031)
5.3 Global Conjunctivitis Average Price by Type (2020-2031)
6 麻豆原创 Segment by End User
6.1 Global Conjunctivitis Sales Quantity by End User (2020-2031)
6.2 Global Conjunctivitis Consumption Value by End User (2020-2031)
6.3 Global Conjunctivitis Average Price by End User (2020-2031)
7 North America
7.1 North America Conjunctivitis Sales Quantity by Type (2020-2031)
7.2 North America Conjunctivitis Sales Quantity by End User (2020-2031)
7.3 North America Conjunctivitis 麻豆原创 Size by Country
7.3.1 North America Conjunctivitis Sales Quantity by Country (2020-2031)
7.3.2 North America Conjunctivitis Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Conjunctivitis Sales Quantity by Type (2020-2031)
8.2 Europe Conjunctivitis Sales Quantity by End User (2020-2031)
8.3 Europe Conjunctivitis 麻豆原创 Size by Country
8.3.1 Europe Conjunctivitis Sales Quantity by Country (2020-2031)
8.3.2 Europe Conjunctivitis Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Conjunctivitis Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Conjunctivitis Sales Quantity by End User (2020-2031)
9.3 Asia-Pacific Conjunctivitis 麻豆原创 Size by Region
9.3.1 Asia-Pacific Conjunctivitis Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Conjunctivitis Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Conjunctivitis Sales Quantity by Type (2020-2031)
10.2 South America Conjunctivitis Sales Quantity by End User (2020-2031)
10.3 South America Conjunctivitis 麻豆原创 Size by Country
10.3.1 South America Conjunctivitis Sales Quantity by Country (2020-2031)
10.3.2 South America Conjunctivitis Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Conjunctivitis Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Conjunctivitis Sales Quantity by End User (2020-2031)
11.3 Middle East & Africa Conjunctivitis 麻豆原创 Size by Country
11.3.1 Middle East & Africa Conjunctivitis Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Conjunctivitis Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Conjunctivitis 麻豆原创 Drivers
12.2 Conjunctivitis 麻豆原创 Restraints
12.3 Conjunctivitis Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Conjunctivitis and Key Manufacturers
13.2 Manufacturing Costs Percentage of Conjunctivitis
13.3 Conjunctivitis Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Conjunctivitis Typical Distributors
14.3 Conjunctivitis Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Companies Mentioned:

Novartis (CH)
Santen Pharmaceutical (JP)
Bausch & Lomb (US)
Allergan (US)
Sun Pharmaceutical (ID)
Akorn (US)
Freda (CN)
Sinqi (CN)
Univision (CN)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.